| |
|
|
Bukwang Pharmaceutical Co.,Ltd (003000) |
|
|
STOCK |
|
|
| Address |
398-1, DAEBANG-DONG, DONGJAK-GU, SEOUL |
| Home Page |
www.bukwang.co.kr
|
| Established |
1960.10.17 |
Tel |
02-828-8114 |
| Listed |
1988. 8. 5 |
IR |
02-828-8034 |
| Common shares O/S |
27,045,225 |
President |
Lee,Seong Gu |
| Preferred shares O/S |
|
No.of Employees |
555(2010. 6) |
| Sales increased on rising demand for its key products such as hepatitis B drug-Rebovir. Profitability remained stable, although its spending on R&D and facilities increased. The company is set to release hepatitis B drug and other new drugs in the second half. |
| Profitability is expected to improve on rising demand for its key products and new products. However, any big improvement in profitability is unlikely due to increased depreciation costs. A state policy to curb rebates is expected to help boost the company's sales. |
|
  |
(date: 2009.12, unit : %) |
| Name |
Kim Dongyeon |
Jeong Changsu |
Kim Gihwan |
| Portion |
25.1 |
11.8 |
5.5 |
|
 |
(unit : %) |
| Sales |
Thioctacid |
11.4 |
Cost |
Raw Materials |
|
| Legalon Suspension |
8.6 |
Labors |
|
| Others |
62.8 |
Overhead |
|
|
 |
(Unit : 100Mn.Won,Won) |
| Year |
99. 6 |
00. 6 |
04.10 |
07. 6 |
08. 6 |
| Type |
SD |
SD |
BI |
SD |
SD |
| Amount |
9.72 |
5.14 |
10.80 |
5.93 |
6.43 |
|
|
|
|
